Cervical cancer is the second most common cancer globally. Four out of every five new cases of cervical cancer are diagnosed in developing countries worldwide.' There is now sufficient evidence to suggest that the risk of developing cervical cancer is sexually transmitted.2 Epidemiological and experimental evidence suggests that human papillomavirus (HPV) is the infectious agent associated with cervical cancer.3 A recent survey of over 1000 specimens of cervical cancer from 22 countries confirmed conclusively that genital HPV is the main aetiological factor in cervical cancer worldwide.4 This study also demonstrated that more than 20 different genital HPV types are associated with cervical cancer from several countries.
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A large study screening biopsy specimens from low/high grade squamous intraepithelial lesions and cervical cancers grouped different genital HPV types according to their prevalence.5 These groups were as follows: HPV 6, 11, 42, 43 26 It thus becomes increasingly apparent that the detection of integrated viral particles in human cervical epithelium may be important in clinical management of HPV associated cervical neoplasia. This was recently demonstrated in a study estimating the four-year disease-free survival of women with stage Ib cervical cancer. 32 Unger et al found that detection of integrated HPV DNA in the primary tumour was strongly associated with treatment failure. This is the first study highlighting the role of viral integration as a prognostic marker in early cervical cancer. Furthermore, HPV detection and integrated state was not associated with any other clinical variable-for example, histopathology, age at diagnosis, type of treatment, or size of lesion. These authors32 used a previously described non-isotopic in situ hybridisation (NISH) assay'9 to determine the integrated state of HPV in cervical cancer tissue. The correlation of NISH pattern (punctate/dot/type 2 signal) with HPV integration as determined by Southern blot hybridisation and two-dimensional gel electrophoresis has been verified previously.'9"" This NISH assay is applicable to archival tissue17 18 and firmly establishes the location of integrated HPV DNA sequences within tumour cells. This overcomes the technical problems of DNA fragmentation (with inadequate DNA extraction), presence of inhibitors and contamination associated with PCR analysis which has been used to determine the physical state of HPV.23 34 The NISH assay is also a molecular technique that can be completed within a single working day, permitting easy access to the diagnostic histopathologist for clinical application.
The NISH assay is also capable of distinguishing integrated from episomal viral sequences on morphological grounds. Hence, type 1 (diffuse) represents episomal HPV, type 2 (dot) integrated HPV, and type 3 (mixed) a combination of episomal and integrated HPV.'9 23 33 Following the description of the single dot and multidot nuclear signal patterns in cervical cancer,23 it was further proposed that these be designated 2a and 2b, respectively.35 These single dot signals may be subtle and indistinct,23 36 raising the need for extreme caution in the interpretation of NISH signal patterns. Such a cautious approach refers not only to false negativity, where subtle signals may be overlooked by the inexperienced observer, but also to false positivity. The need for a clean background both within the nucleus and on the slide cannot be overemphasised to prevent technical artefact from being misinterpreted as a positive signal. 35 The converse is also true for the type 1/diffuse intranuclear signal where a subtle hint of "blush" may also be missed. 36 A further problem is that occasional tumours may demonstrate HPV DNA NISH type 2/dot signals in an isolated focal single cell distribution.'8 The significance of this pattern has not been elucidated in cervical carcinogenesis, but it is nevertheless plausible to assume that such a detection threshold may well be below that of Southern blot analysis of viral copies/cell. A highly specific and sensitive in situ hybridisation system has been shown to detect 10 viral copies/cell.37 In addition, these single type 2/dot signals indicating integrated virus, may also coexist with diffuse staining, varying copy number, episomal virus in cervical cancers. 18 19 23 33 This therefore raises interesting questions about the sensitivity of Southern analysis in the determination of the physical state of HPV, as viral-host chromosome junction fragments essential for determining isolated integrated virus in a tumour may be masked by a greater viral copy number of episomal virus. 35 In summary, the role of NISH in the determination of the physical state of HPV in cervical preneoplastic/neoplastic lesions has now been confirmed by three independent laboratories using all available molecular investigative techniques.9 23 This issue takes us into our third year. Our change of name is not merely cosmetic; our Editorial Board were in accord that the aims and content of the journal would be represented better by the exclusion of the word "clinical" from our title. This does not mean that we do not want to publish material with a clinical emphasis. Our ethos has always been to supplement the content of the Jtournal of Clinical Pathology with papers and reviews that include pure science which furthers our understanding of disease mechanisms. Molecular Pathology is, therefore, a title which represents accurately the aims and content of this journal. After only two volumes, Molecular Pathology has over 2000 institutional subscribers worldwide and a combined (with Jrournal of Clinical Pathology) impact factor of 1.607. Molecular Pathology is indexed in Index Medicus and Current Contents. This is very creditable for so young a publication and indicates that Molecular Pathology is being read and cited by many of our co-workers. We hope that you will continue to support and enjoy Molecu- 
